A mathematical modeling approach to understanding the effect of anti-interleukin therapy on Eosinophils

CPT: Pharmacometrics and Systems Pharmacology

Volumn 5, Issue 11, 2016, Pages 608-616

  Karelina, T ^a   Voronova, V ^a   Demin, O ^a   Colice, G ^b   Agoram, B M ^c  

^a Institute for Systems Biology   (Russian Federation)

^b ASTRAZENECA   (United Kingdom)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; EOTAXIN; INTERLEUKIN 13; INTERLEUKIN 5; LEBRIKIZUMAB; MEPOLIZUMAB; TRALOKINUMAB; TRANSCRIPTION FACTOR RUNX2; INTERLEUKIN-13, HUMAN; MONOCLONAL ANTIBODY;

AIRWAY CELL; ARTICLE; ASTHMA; ASTHMATIC STATE; CELL MATURATION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG MECHANISM; EOSINOPHIL; HUMAN; LEUKOCYTE MIGRATION; MATHEMATICAL MODEL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; TH2 CELL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; DRUG EFFECTS; IMMUNOLOGY; RESPIRATORY SYSTEM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; EOSINOPHILS; HUMANS; INTERLEUKIN-13; MODELS, BIOLOGICAL; RESPIRATORY SYSTEM;

EID: 84999885019     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12129     Document Type: Article

References (48)

1. Mitchell, J., Dimov, V., & Townley, R.G. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. Curr. Opin. Investig. Drugs 11, 527-534 (2010
2. May, R.D., et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br. J. Pharmacol. 166, 177-193 (2012
3. Murray, L.A., et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am. J. Respir. Cell Mol. Biol. 50, 985-994 (2014
4. Piper, E., et al. A phase II placebo-controlled study of tralokinumab in moderate-Tosevere asthma. Eur. Respir. J. 41, 330-338 (2013
5. Brightling, C.E., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir. Med. 2, 891-901 (2014
6. Castro, M., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184, 1125-1132 (2011
7. Wenzel, S., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455-2466 (2013
8. Noonan, M., et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J. Allergy Clin. Immunol. 132, 567-574 (2013
9. Hanania, N.A., et al. Lebrikizumab in moderate-To-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70, 748-756 (2015
10. Corren, J., et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088-1098 (2011
11. Vogel, R., et al. Modeling and simulation in science, engineering and technology. pp 144-155 (eds. Deutsch, A., et al.) Mathematical Modeling of Biological Systems, Volume II (Springer, New York, NY, 2008
12. Kim, Y., et al. Regulation of Th1/Th2 cells in asthma development: a mathematical model. Math. Biosci. Eng. 10, 1095-1133 (2013
13. Walsh, E.R., Thakar, J., Stokes, K., Huang, F., Albert, R., & August, A. Computational and experimental analysis reveals a requirement for eosinophil-derived IL-13 for the development of allergic airway responses in C57BL/6 mice. J. Immunol. 186, 2936-2949 (2011
14. Demin, O., et al. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT Pharmacometrics Syst. Pharmacol. 2, e74 (2013
15. Clutterbuck, E.J., Hirst, E.M., & Sanderson, C.J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73, 1504-1512 (1989
16. Moore, P.E., Church, T.L., Chism, D.D., Panettieri, R.A. Jr & Shore, S.A. IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L847-L853 (2002
17. Dubucquoi, S., et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J. Exp. Med. 179, 703-708 (1994
18. Cherry, W.B., Yoon, J., Bartemes, K.R., Iijima, K., & Kita, H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121, 1484-1490 (2008
19. Luttmann, W., Matthiesen, T., Matthys, H., & Virchow J.C. Jr. Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor-Alpha on eosinophil activation in vitro. Am. J. Respir. Cell Mol. Biol. 20, 474-480 (1999
20. Fujisawa, T., et al. Chemokines induce eosinophil degranulation through CCR-3. J. Allergy Clin. Immunol. 106, 507-513 (2000
21. Huang, C.D., et al. Eosinophils from asthmatics release IL-5 in an autocrine fashion to prevent apoptosis through upregulation of Bcl-2 expression. J. Asthma 42, 395-403 (2005
22. Schmid-Grendelmeier, P., et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J. Immunol. 169, 1021-1027 (2002
23. Farahi, N., et al. Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance. Clin. Exp. Allergy 41, 673-687 (2011
24. Kumagai, N., Fukuda, K., Ishimura, Y., & Nishida, T. Synergistic induction of eotaxin expression in human keratocytes by TNF-Alpha and IL-4 or IL-13. Invest. Ophthalmol. Vis. Sci. 41, 1448-1453 (2000
25. Fregonese, L., Silvestri, M., Sabatini, F., & Rossi, G.A. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin. Exp. Allergy 32, 745-750 (2002
26. Stein, M.L., et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J. Allergy Clin. Immunol. 121, 1473-1483 (2008
27. Flood-Page, P.T., Menzies-Gow, A.N., Kay, A.B., & Robinson, D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167, 199-204 (2003
28. Gizzatkulov, N.M., Goryanin, I.I., Metelkin, E.A., Mogilevskaya, E.A., Peskov, K.V., & Demin, O.V. DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results. BMC Syst. Biol. 4, 109 (2010
29. Grootendorst, D.C., et al. Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin. Exp. Allergy 27, 769-779 (1997
30. Bogic, M., et al. Clinical significance of measurement of interleukin 4 and interleukin 5 serum concentrations in bronchial asthma. Jugoslov. Med. Biohem. 23, 51-54 (2004
31. Wiesemann, E., Klatt, J., Wenzel, C., Heidenreich, F., & Windhagen, A. Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis. Clin. Exp. Immunol. 133, 454-460 (2003
32. Jahnz-Royk, K., Plusa, T., & Mierzejewska, J. Eotaxin in serum of patients with asthma or chronic obstructive pulmonary disease: relationship with eosinophil cationic protein and lung function. Mediators Inflamm. 9, 175-179 (2000
33. Kabata, H., et al. Relationship between serum periostin levels and severity/phenotype of asthma. Respir. Crit. Care Med. American Thoracic Society International Conference Abstracts. (2013
34. Flood-Page, P., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176, 1062-1071 (2007
35. Buttner, C., Lun, A., Splettstoesser, T., Kunkel, G., & Renz, H. Monoclonal antiinterleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur. Respir. J. 21, 799-803 (2003
36. Walsh, G.M. Mepolizumab and eosinophil-mediated disease. Curr. Med. Chem. 16, 4774-4778 (2009
37. Simon, H.U., Yousefi, S., Schranz, C., Schapowal, A., Bachert, C., & Blaser, K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J. Immunol. 158, 3902-3908 (1997
38. Haldar, P., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973-984 (2009
39. Straumann, A., et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59, 21-30 (2010
40. Laviolette, M., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 132, 1086-1096 (2013
41. Yamaguchi, Y., et al. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br. J. Dermatol. 168, 717-725 (2013
42. Jia, G., et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J. Allergy Clin. Immunol. 130, 647-654 (2012
43. Bree, A., et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J. Allergy Clin. Immunol. 119, 1251-1257 (2007
44. Brightling, C.E., et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 3, 692-701 (2015
45. Ohshima, N., et al. A functional study on CysLT(1) receptors in human eosinophils. Int. Arch. Allergy Immunol. 129, 67-75 (2002
46. Sehmi, R., Wardlaw, A.J., Cromwell, O., Kurihara, K., Waltmann, P., & Kay, A.B. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 79, 2952-2959 (1992
47. Till, S., et al. Secretion of the eosinophil-Active cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by bronchoalveolar lavage CD41 and CD81 T cell lines in atopic asthmatics, and atopic and non-Atopic controls. Eur. J. Immunol. 25, 2727-2731 (1995
48. Ochi, H., De Jesus, N.H., Hsieh, F.H., Austen, K.F., & Boyce, J.A. IL-4 and 25 prime human mast cells for different profiles of IgE-dependent cytokine production. Proc. Natl. Acad. Sci. USA 97, 10509-10513 (2000